A Systematic Review and Bioinformatics Study on Genes and micro-RNAs Involving the Transformation of Endometriosis into Ovarian Cancer

Author(s): Mehrdad Sheikhvatan, Shahla Chaichian*, Bahram Moazzami.

Journal Name: MicroRNA

Volume 9 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Along with the description of tumorigenesis processes in endometriosisrelated ovarian cancer, identifying dysregulated miRNAs, the target genes of these miRNAs, and the processes abnormally affected by dysregulated miRNAs is essential, which was our goal.

Methods: Two reviewers individually evaluated the articles which collected relevant information including genes and miRNAs involved in the transformation of endometriosis into ovarian cancer. To assess the mature sequence of miRNAs and also their chromosomal positions, miRPathDB software was employed. To determine the main target gene predicted for each considered miRNAs, the TargetScanS Web server was applied. The interaction of each gene with other genes associated with endometrial- related ovarian cancer was determined by GeneMANIA software. Finally, to design integrated model of miRNAs-targeted genes interaction network, the Cytoscape software was used.

Results: The final number of studies available for analysis was 6 manuscripts including 22 miRNAs described as involved in the transformation of endometriosis into different subtypes of ovarian cancers (14 miRNAs up-regulated and 8 miRNAs down-regulated). Three miRNAs of miR-141 (upregulated), miR-205 (down-regulated), and miR-125b (down-regulated) were revealed as the originator for genetic interactions leading to carcinogenesis. We could show some common loops and pathways including uncontrolled cell proliferation and abnormal apoptosis (mediated by PTEN gene induced by miR-21 and miR-214), and disaggregation and epithelialization (mediated by ZEB1 and ZEB2 genes induced by miR-200).

Conclusion: According to our analysis, up-regulation of miR-141 and down-regulation of miR-205 and miR-125b have a central role in transforming endometriosis to ovarian cancer.

Keywords: Endometriosis, gene, miRNAs, ovarian cancer, cell carcinoma, EGF.

[1]
Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinicalmanagement. Curr Obstet Gynecol Rep 2017; 6(1): 34-41.
[http://dx.doi.org/10.1007/s13669-017-0187-1] [PMID: 29276652]
[2]
Dun EC, Kho KA, Kearney S, Nezhat CH. Endometriosis in adolescents: referrals, diagnosis, treatment, and outcomes. J Minim Invasive Gynecol 2015; 22(6S): S176.
[http://dx.doi.org/10.1016/j.jmig.2015.08.650] [PMID: 27678955]
[3]
Chaichian S, Kabir A, Mehdizadehkashi A, Rahmani K, Moghimi M, Moazzami B. Comparing the efficacy of surgery and medical therapy for pain management in endometriosis: a systematic review and meta-analysis. Pain Physician 2017; 20(3): 185-95.
[PMID: 28339429]
[4]
Chene G, Ouellet V, Rahimi K, Barres V, Provencher D, Mes-Masson AM. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis. Int J Gynaecol Obstet 2015; 130(1): 27-30.
[http://dx.doi.org/10.1016/j.ijgo.2015.02.021] [PMID: 25912412]
[5]
Matsumoto T, Yamazaki M, Takahashi H, et al. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. Am J Clin Pathol 2015; 144(3): 452-63.
[http://dx.doi.org/10.1309/AJCPZ5T2POOFMQVN] [PMID: 26276776]
[6]
Sampson JA. Endometrial carcinoma of ovary arising in endometrial tissue in that organ. Arch Surg 1925; 10: 1-72.
[http://dx.doi.org/10.1001/archsurg.1925.01120100007001]
[7]
Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004; 18(2): 349-71.
[http://dx.doi.org/10.1016/j.bpobgyn.2003.03.001] [PMID: 15157647]
[8]
Zafrakas M, Grimbizis G, Timologou A, Tarlatzis BC. Endometriosis and ovarian cancer risk: a systematic review of epidemiological studies. Front Surg 2014; 8(1): 14.
[9]
Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155(3): 217-24.
[http://dx.doi.org/10.1093/aje/155.3.217] [PMID: 11821246]
[10]
Borgfeldt C, Andolf E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 2004; 83(4): 395-400.
[http://dx.doi.org/10.1111/j.0001-6349.2004.00305.x] [PMID: 15005789]
[11]
Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004; 191(3): 733-40.
[http://dx.doi.org/10.1016/j.ajog.2004.03.035] [PMID: 15467532]
[12]
Olson JE, Cerhan JR, Janney CA, Anderson KE, Vachon CM, Sellers TA. Postmenopausal cancer risk after self-reported endometriosis diagnosis in the Iowa women’s health study. Cancer 2002; 94(5): 1612-8.
[http://dx.doi.org/10.1002/cncr.10370] [PMID: 11920519]
[13]
Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13(4): 385-94.
[http://dx.doi.org/10.1016/S1470-2045(11)70404-1] [PMID: 22361336]
[14]
Giudice LC, Kao LC. Endometriosis. Lancet 2004; 364(9447): 1789-99.
[http://dx.doi.org/10.1016/S0140-6736(04)17403-5] [PMID: 15541453]
[15]
Gazvani R, Templeton A. New considerations for the pathogenesis of endometriosis. Int J Gynaecol Obstet 2002; 76(2): 117-26.
[http://dx.doi.org/10.1016/S0020-7292(01)00577-X] [PMID: 11818105]
[16]
Jiang X, Hitchcock A, Bryan EJ, et al. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 1996; 56(15): 3534-9.
[PMID: 8758923]
[17]
Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000; 60(24): 7052-6.
[PMID: 11156411]
[18]
Ramaswamy S, Nakamura N, Vazquez F, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999; 96(5): 2110-5.
[http://dx.doi.org/10.1073/pnas.96.5.2110] [PMID: 10051603]
[19]
Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011; 225(2): 189-94.
[http://dx.doi.org/10.1002/path.2940] [PMID: 21735444]
[20]
Treiber T, Treiber N, Meister G. Author correction: Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol 2018; 19(12): 808.
[http://dx.doi.org/10.1038/s41580-018-0070-6] [PMID: 30270345]
[21]
Olena AF, Patton JG. Genomic organization of microRNAs. J Cell Physiol 2010; 222(3): 540-5.
[http://dx.doi.org/10.1002/jcp.21993] [PMID: 20020507]
[22]
O’Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol 2012; 30: 295-312.
[http://dx.doi.org/10.1146/annurev-immunol-020711-075013] [PMID: 22224773]
[23]
Saito H, Liang G, Friedman JM. Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review. Clin Rev Allergy Immunol 2014; 47(2): 128-35.
[http://dx.doi.org/10.1007/s12016-013-8401-z] [PMID: 24362548]
[24]
Dou YD, Huang T, Wang Q, et al. Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer. Biochem Biophys Res Commun 2018; 496(1): 191-8.
[http://dx.doi.org/10.1016/j.bbrc.2018.01.023] [PMID: 29307835]
[25]
Wang L, Zhu MJ, Ren AM, et al. A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. PLoS One 2014; 9(5) e96472
[http://dx.doi.org/10.1371/journal.pone.0096472] [PMID: 24816756]
[26]
Teague EM, Print CG, Hull ML. The role of microRNAs in endometriosis and associated reproductive conditions. Hum Reprod Update 2010; 16(2): 142-65.
[http://dx.doi.org/10.1093/humupd/dmp034] [PMID: 19773286]
[27]
Suryawanshi S, Vlad AM, Lin HM, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 2013; 19(5): 1213-24.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-2726] [PMID: 23362326]
[28]
Wu R. Identification of differentially expressed miRNAs in ovarian cancer from endometriosis in the same patient. Gynecol Oncol 2014; 133: 95.
[http://dx.doi.org/10.1016/j.ygyno.2014.03.252]
[29]
Dong M, Yang P, Hua F. MiR-191 modulates malignant transformation of endometriosis through regulating TIMP3. Med Sci Monit 2015; 21: 915-20.
[http://dx.doi.org/10.12659/MSM.893872] [PMID: 25819812]
[30]
Chang CY, Lai MT, Chen Y, et al. Up-regulation of ribosome biogenesis by MIR196A2 genetic variation promotes endometriosis development and progression. Oncotarget 2016; 7(47): 76713-25.
[http://dx.doi.org/10.18632/oncotarget.11536] [PMID: 27741504]
[31]
Braicu OL, Budisan L, Buiga R, et al. miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples. OncoTargets Ther 2017; 28(10): 4225-38.
[32]
Schöndorf T, Ebert MP, Hoffmann J, et al. Hypermethylation of the PTEN gene in ovarian cancer cell lines. Cancer Lett 2004; 207(2): 215-20.
[http://dx.doi.org/10.1016/j.canlet.2003.10.028] [PMID: 5072831]
[33]
Yang Y, Ahn YH, Chen Y, et al. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 2014; 124(6): 2696-708.
[http://dx.doi.org/10.1172/JCI72171] [PMID: 24762440]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 2
Year: 2020
Page: [101 - 111]
Pages: 11
DOI: 10.2174/2211536608666190917152104

Article Metrics

PDF: 25
HTML: 7